Schematic representation of CAR structures as well as known and potential therapeutic targets for CAR-T cell therapy in cancers. (A) CARs consist of a monoclonal antibody-derived scFv, a hinge region, a transmembrane domain, and intracellular signaling domains containing one or more endodomains of costimulatory molecules and/or a TCR. The four generations of CAR are shown. (B) Known, and potential, therapeutic targets in hematological and solid cancers for CAR-T cell therapy are provided. These include B-cell maturation antigen (BCMA), carcinoembryonic antigen (CEA), epidermal growth factor receptor variant III (EGFRvIII), the disiaoganglioside GD2, glypican-3 (GPC-3), human epidermal growth factor receptor 2 (HER2), and interleukin 13 receptor subunit alpha 2 (IL13RA2).